AdaptivCRT Algorithm Put To The Test In Medtronic’s Superiority Trial

This article was originally published in The Gray Sheet

27 Aug 2014
News

Executive Summary

The first of a planned 3,000 patients have been enrolled in the AdaptResonse trial of Medtronic’s AdaptivCRT cardiac resynchronization algorithm. Previous studies have shown the algorithm reduces hospitalizations, and Medtronic hopes AdaptResponse will show it reduces mortality and medical interventions.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Related Companies

Medtronic PLC

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT033267

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT033267

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

AdaptivCRT Algorithm Put To The Test In Medtronic’s Superiority Trial

News

Executive Summary

Related Content

Medtronic Claims Clinical, Cost Advantages For Just-Launched Viva CRT-D

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert